{"id":801374,"date":"2025-01-16T03:03:07","date_gmt":"2025-01-16T08:03:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bioworld-by-clarivate-releases-comprehensive-2024-year-in-review\/"},"modified":"2025-01-16T03:03:07","modified_gmt":"2025-01-16T08:03:07","slug":"bioworld-by-clarivate-releases-comprehensive-2024-year-in-review","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bioworld-by-clarivate-releases-comprehensive-2024-year-in-review\/","title":{"rendered":"BioWorld by Clarivate Releases Comprehensive 2024 Year in Review"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Series Recaps Biopharma, MedTech, and Science Trends and Breakthroughs That Shaped the Year<\/i>\n <\/p>\n

\n
\n LONDON<\/span>
\n <\/span>, Jan. 16, 2025<\/span><\/span> \/PRNewswire\/ — BioWorld\u2122 published by Clarivate Plc<\/a>\u00a0(NYSE:CLVT), a leading global provider of transformative intelligence, has released its highly anticipated 2024 Year in Review<\/a> series. This multipart special report offers an in-depth analysis of the therapeutic trends, regulatory actions and economic shifts that defined biopharma, med tech and scientific innovation over the past year while forecasting key developments for 2025.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Clarivate
\n <\/a>\n <\/p>\n<\/p><\/div>\n

As the biopharma and med-tech industries continue to evolve, 2024 proved to be a landmark year. The comprehensive recap by BioWorld highlights therapeutic breakthroughs in psychiatry, oncology, women’s health and infectious diseases, alongside economic highs and lows that challenged the global landscape. The series also examines regulatory changes, including U.S. court cases and international policy shifts, that could shape the future of drug pricing, reimbursement, and innovation.<\/p>\n

\n
\n Lynn Yoffee<\/span>, Publisher of BioWorld, said:<\/b>\u00a0“The 2024 Year in Review series provides a powerful lens into the transformative events and advancements that shaped our industry this year. With our team of expert journalists and analysts, we strive to distill complex developments into actionable insights, empowering stakeholders to make informed decisions as they navigate 2025 and beyond.”<\/p>\n

\n Key Highlights of the BioWorld 2024 Year in Review Series:<\/b>\n <\/p>\n

\n
\n BioWorld Year in Review<\/a>
\n <\/b>
\n :<\/b>\u00a0This section highlights the top mergers and acquisitions, licensing deals, financings, and first approvals of 2024. It also provides insights into key therapeutic trends such as GLP-1 receptor agonists, antibody-drug conjugates (ADCs), psychedelics, and the evolving role of precision psychiatry, alongside innovations spurred by the pandemic. Featured articles include:<\/p>\n